1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

ASEAN issues call for dengue action as cases rise

 
• By Ian Haydock

The 10 member countries of ASEAN (the Association of Southeast Asian Nations) have agreed to collaborate more closely on the prevention, surveillance and treatment of dengue amid a steady rise in the incidence of the disease.

The 10 member countries of ASEAN (the Association of Southeast Asian Nations) have agreed to collaborate more closely on the prevention, surveillance and treatment of dengue amid a steady rise in the incidence of the disease.

The regional economic grouping issued a call to action following a regional conference and first official "Dengue Day" held in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

Valneva Secures $500m Financing Ahead Of Lyme Disease Vaccine Readout

 
• By Kevin Grogan

The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.

Enanta Plans Phase III Trial Of Zelicapavir Despite Primary Endpoint Miss

 
• By Alaric DeArment

The company announced Phase IIb results for the RSV drug that showed positive data across multiple key secondary endpoints, some of which could serve as a primary endpoint in Phase III.

Having Steadied GSK’s Ship, Walmsley To Step Down As Chief

 
• By Kevin Grogan

Chief commercial officer Luke Miels to take over in 'seamless succession'.

Seres Cuts Jobs To Fund Next Microbiome Bet As Cash Runs Low

 
• By Manas Mishra

The biotech is to cut a quarter of its workforce, extending its cash runway to Q2 2026 as it plans a Phase II study for its live biotherapeutic to prevent bloodstream infections.

More from Therapeutic Category

Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups

 
• By Joseph Haas

With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.

Boehringer’s Jascayd Approval Brings New Mechanism To IPF

 
• By Jessica Merrill

The PDE4B inhibitor brings a new mechanism of action to the challenging respiratory disease and is the first drug approved for the indication in more than a decade.

Valneva Secures $500m Financing Ahead Of Lyme Disease Vaccine Readout

 
• By Kevin Grogan

The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.